Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett Sells 14,380 Shares

Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the sale, the chief financial officer now owns 47,476 shares in the company, valued at approximately $760,090.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Immunome Trading Down 2.0 %

Shares of NASDAQ IMNM opened at $14.99 on Friday. The firm’s 50-day moving average price is $14.51 and its 200-day moving average price is $16.24. The stock has a market capitalization of $898.94 million, a price-to-earnings ratio of -1.99 and a beta of 1.77. Immunome, Inc. has a 12-month low of $6.65 and a 12-month high of $30.96.

Immunome (NASDAQ:IMNM) last announced its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The business had revenue of $2.36 million for the quarter, compared to analysts’ expectations of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. On average, equities analysts predict that Immunome, Inc. will post -1.92 EPS for the current fiscal year.

Institutional Trading of Immunome

Several hedge funds have recently made changes to their positions in the business. Northeast Financial Consultants Inc purchased a new stake in shares of Immunome during the 2nd quarter valued at about $883,000. The Manufacturers Life Insurance Company raised its position in Immunome by 52.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 166,928 shares of the company’s stock worth $2,020,000 after purchasing an additional 57,242 shares during the period. AQR Capital Management LLC raised its position in Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after purchasing an additional 4,129 shares during the period. AXA S.A. purchased a new stake in Immunome in the 2nd quarter worth about $2,174,000. Finally, Marshall Wace LLP raised its position in Immunome by 228.5% in the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after purchasing an additional 1,191,774 shares during the period. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on IMNM. Wedbush reiterated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Tuesday, August 13th. Piper Sandler decreased their price target on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Immunome presently has an average rating of “Buy” and a consensus target price of $29.00.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.